Synovial sarcoma occurring in a patient under 18 years of age is a distinct and uncommon presentation. The disease is rare in the pediatric population, making it difficult to conduct randomized pediatric-specific clinical trials. The optimal approach to treatment in this age group is now better defined, though it requires careful clinical judgement.
For relapsing synovial sarcoma in this age group, management includes a multimodal strategy combining surgical and systemic interventions — the full sequence, options, and structured regimen are detailed in the complete protocol.
DOI: 10.1016/j.esmoop.2023.101618
The optimal approach to the treatment of SS in pediatric patients is now better defined.
The disease is rare in the pediatric population, making it difficult to conduct randomized pediatric SS-specific clinical trials.
Approaches to relapsing SS in children have included additional surgery, second-line chemotherapy (e.g. with ifosfamide combinations), and radiotherapy.
View source ↗